Document Detail

Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
MedLine Citation:
PMID:  7685834     Owner:  NLM     Status:  MEDLINE    
We have developed a new hypersensitive enzyme immunoassay for prostate specific antigen (PSA) based on the (MARKIT-M PA) assay but employing a two-hour incubation of the primary monoclonal antibody. The analytical sensitivity has been determined at 0.2 ng/ml, calculated as the mean+three standard deviations of the zero calibrator. Serum PSA was measured at least one month after radical prostatectomy (nine patients) or cystoprostatectomy (six patients). Based on the PSA levels of these patients, the recommended PSA cut-off level indicative of residual disease after radical prostatectomy was 0.4 ng/ml. Increasing (> 0.4 ng/ml) PSA levels preceded recurrence by eight months in a patient who developed bone metastasis after radical prostatectomy. In two patients treated with endocrine therapy, increasing PSA levels also preceded clinical evidence of progression by between eight and nine months. The study suggests that the newly developed sensitive PSA assay allows for the identification of patients with disease progression and the early commencement of adjuvant treatment.
Y Arai; H Onishi; K Oishi; H Takeuchi; O Yoshida
Related Documents :
2152694 - Treatment of hormonally refractory cancer of the prostate with antineoplaston as2-1.
7285324 - Increased inactive creatine kinase b protein in the plasma of patients with malignancy.
10661684 - Ca 19-9 and cea are unreliable markers for cholangiocarcinoma in patients with primary ...
17112774 - Epidermal growth factor receptor (egfr) polymorphisms and survival in head and neck can...
23263384 - Quantitative t2 measurements in juvenile and late infantile neuronal ceroid lipofuscino...
23180324 - Safety and efficacy of the gunther tulip retrievable vena cava filter: midterm outcomes.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Japanese journal of clinical oncology     Volume:  23     ISSN:  0368-2811     ISO Abbreviation:  Jpn. J. Clin. Oncol.     Publication Date:  1993 Apr 
Date Detail:
Created Date:  1993-07-22     Completed Date:  1993-07-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0313225     Medline TA:  Jpn J Clin Oncol     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  110-5     Citation Subset:  IM    
Department of Urology, Faculty of Medicine, Kyoto University.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Immunoenzyme Techniques
Prostate-Specific Antigen / blood*
Prostatic Hyperplasia / immunology
Prostatic Neoplasms / immunology*,  therapy
Regression Analysis
Reproducibility of Results
Sensitivity and Specificity
Reg. No./Substance:
EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low dose lidocaine combined with magnesium sulfate in warning ventricular arrhythmias.
Next Document:  Cisplatin, vindesine, pepleomycin and combined radiation therapy for inoperable esophageal carcinoma...